Abstract: The invention refers to the use of Lactobacillus plantarum 299v having a mannose-specific adhesin for the preparation of a pharmaceutical composition inhibiting the binding of pathogenic bacteria expressing mannose-specific adhesins to the epithelial cell surface. The strain of Lactobacillus plantiarum which can be used in the invention adheres to D-mannose-coated agarose beads. The invention also refers to the use of said strain for the preparation of a pharmaceutical composition to be used in prophylatic and/or curative treatment of bacterial translocation, gastroenteritis and other diseases caused by pathogenic bacteria expressing mannose-specific adhesins.
Abstract: A process for isolation of a strain of Lactobacillus having the ability of being established on human intestinal mucosa in vivo and being able to remain therein after oral administration for at least 10 days after the completion of the administration. By the process the new strains L. plantarum 299 (DSM 6595) and L. casei ssp. rhamnosus 271 (DSM 6594) have been isolated, which are useful for the prophylaxis or treatment of bacterial infections, especially in the form of a fermented nutrient composition.
Abstract: A process for isolation of a strain of Lactobacillus having the ability of being established on human intestinal mucosa in vivo and being able to remain therein after oral administration for at least 10 days after the completion of the administration. By the process the new strains L. plantarum 299 (DSM 6595) and L. casei ssp. rhamnosus 271 (DSM 6594) have been isolated, which are useful for the prophylaxis or treatment of bacterial infections, especially in the form of a fermented nutrient composition.
Abstract: A process for isolation of a strain of Lactobacillus having the ability of being established on human intestinal mucosa in vivo and being able to remain therein after oral administration for at least 10 days after the completion of the administration.By the process the new strains L. plantarum 299 (DSM 6595) and L. casei ssp. rhamnosus 271 (DSM 6594) have been isolated, which are useful for the prophylaxis or treatment of bacterial infections, especially in the form of a fermented nutrient composition.
Abstract: A nutrient composition for administration to patients in, for example, feeding by tube, or for use as a health drink is described. The nutrient composition comprises a fermented cereal-based product, enzyme and, optionally, further nutrient components, in combination with lactobacilli. Also described is a method of preparing a nutrient composition for administration to patients, inter alia in feeding by tube, or for use as a health drink, in which method a cereal flour is mixed with water, a-amylase and, optionally, a protease, the mixture is brought to the boil under agitation, allowed to cool and mixed with B-glucanase which is allowed to act until the viscosity of the mixture has decreased to below 0.020 Pas, whereupon the mixture is fermented.
Type:
Grant
Filed:
November 9, 1990
Date of Patent:
March 2, 1993
Assignee:
Probi AB
Inventors:
Nils Molin, Carl-Erik Albertsson, Stig Bengmark, Kare Larsson